Medical Affairs

Innoviva Specialty Therapeutics has created this website as a tool for healthcare professionals in the United States. The information presented on this platform is solely for informational purposes and is not meant to advertise or endorse the use of any particular product.

Publications & Presentations

Information provided in these publications, posters and presentations is intended for scientific review by medical professionals. This information is not considered medical advice and is not intended to promote the sale of any drug product.

For more information on GIAPREZA, including important safety information, please visit www.GIAPREZA.com.

For more information on XERAVA, including important safety information, please visit www.XERAVA.com.

For more information on XACDURO, including important safety information, please visit www.XACDURO.com.

Filter by Product

Marketed

Investigational

No results

XACDURO®

IDSA 2024 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections

Author Name

Tamma PD, Heil EL, Justo JA, Mathers AJ, Satlin MJ, & Bonomo RA

Date Published

July 2024

XERAVA®

The Surgical Infection Society Guidelines on the Management of Intra-Abdominal Infection: 2024 Update

Author Name

Huston JM, Barie PS, Dellinger EP, Forrester JD, Duane TM, Tessier JM, Sawyer RG, Cainzos MA, Rasa K, Chipman JG, Kao LS, Pieracci FM, Colling KP, Heffernan DS, Lester J

Date Published

July 2024

Zoliflodacin

Antimicrobial susceptibility of baseline Neisseria gonorrhoeae isolates from participants recruited in the global zoliflodacin Phase 3 randomised controlled trial

Author Name

Luckey A, Elango V, Bettiol E, Piddock L, Unemo M, Bradford P, McLeod S, Mueller J, Srinivasan S

Date Published

April 2024

Zoliflodacin

Safety profile of oral zoliflodacin for uncomplicated gonorrhoea in a Phase 3 trial

Author Name

Kornmann G, Johnstone H, Wansom T, Srinivasan S, Lewis D, Luckey A

Date Published

April 2024

Zoliflodacin

Pharmacokinetics of zoliflodacin in healthy participants in the presence of itraconazole suggest no clinically meaningful CYP3A4-mediated drug-drug interactions

Author Name

Luckey A, Rayad N, Heep M, Delhomme S, Kornmann G, Larson KB, Mueller JP, O’Donnell JP, O’Brien S, Fuhr R, Gillon JY

Date Published

April 2024

XACDURO®

Current treatment options for pneumonia caused by carbapenem-resistant Acinetobacter baumannii

Author Name

Franzone JP, Mackow NA, van Duin D

Date Published

April 2024

GIAPREZA®

Dysfunction of the renin-angiotensin-aldosterone system in human septic shock

Author Name

Schaich CL, Leisman DE, Goldberg MB, Filbin MR, Khanna AK, Chappell MC

Date Published

March 2024

Zoliflodacin

The formulation of zoliflodacin for commercial use is bioequivalent to the Phase 3 pivotal trial formulation in fed and fasted states

Author Name

Noha Rayad*, Alison Luckey*, Markus Heep, Sophie Delhomme, Gabrielle Kornmann, Kajal B Larson, John P Mueller, John P O’Donnell, Seamus O’Brien, Rainard Fuhr, Jean-Yves Gillon

Date Published

March 2024

GIAPREZA®

Renin Levels and Angiotensin II Responsiveness in Vasopressor-Dependent Hypotension

Author Name

See EJ, Chaba A, Spano S, Maeda A, Clapham C, Burrell LM, Liu J, Khasin M, Liskaser G, Eastwood G, Bellomo R

Date Published

March 2024

GIAPREZA®

Plasma renin as a novel prognostic biomarker of sepsis-associated acute respiratory distress syndrome

Author Name

Chakradhar A, Baron RM, Vera MP, Devarajan P, Chawla L, Hou PC

Date Published

March 2024

XACDURO®

In vitro activity of sulbactam-durlobactam against colistin-resistant and/or cefiderocol-non-susceptible, carbapenem-resistant Acinetobacter baumannii collected in U.S. hospitals

Author Name

Iovleva A, McElheny CL, Fowler EL, Cober E, Herc ES, Arias CA, Hill C, Baum K, Fowler VG Jr, Chambers HF, Greenwood-Quaintance KE, Patel R, van Duin D, Bonomo RA, Doi Y

Date Published

March 2024

XACDURO®

Sulbactam-durlobactam: a β-lactam/β-lactamase inhibitor combination targeting Acinetobacter baumannii

Author Name

McLeod SM, O'Donnell JP, Narayanan N, Mills JP, Kaye KS

Date Published

March 2024

GIAPREZA®

Clinical Response to Third-Line Angiotensin-II vs Epinephrine in Septic Shock: A Propensity-Matched Cohort Study

Author Name

Blankenship CR, Betthauser KD, Hencken LN, Maamari JA, Goetz J, Giacomino BD, Gibson GA

Date Published

February 2024

GIAPREZA®

A Pilot Study of Renin-Guided Angiotensin-II Infusion to Reduce Kidney Stress After Cardiac Surgery

Author Name

Sadjadi M, von Groote T, Weiss R, Strauß C, Wempe C, Albert F, Langenkämper M, Landoni G, Bellomo R, Khanna AK, Coulson T, Meersch M, Zarbock A

Date Published

January 2024

XACDURO®

Sulbactam-Durlobactam, A Novel Drug for the Treatment of Multidrug-resistant Acinetobacter baumannii Infections – A Systematic Review

Author Name

Velmurugan H, Venkatesan S, Meles HN, Thangaraju P, Neelambaram

Date Published

January 2024

GIAPREZA®

Angiotensin II

Author Name

Bellomo R, Zarbock A, Landoni G

Date Published

January 2024

GIAPREZA®

Angiotensin II treatment is associated with improved oxygenation in ARDS patients with refractory vasodilatory shock

Author Name

Leisman DE, Handisides DR, Chawla LS, Albertson TE, Busse LW, Boldt DW, Deane AM, Gong MN, Ham KR, Khanna AK, Ostermann M, McCurdy MT, Thompson BT, Tumlin JS, Adams CD, Hodges TN, Bellomo R

Date Published

December 2023

XACDURO®

Cefiderocol and Sulbactam-Durlobactam against Carbapenem-Resistant Acinetobacter baumannii

Author Name

Karruli A, Migliaccio A, Pournaras S, Durante-Mangoni E, Zarrilli R

Date Published

December 2023

GIAPREZA®

Is It Time to Reconsider the Concept of “Salvage Therapy” in Refractory Shock?

Author Name

Wieruszewski PM, Sevransky JE, Roberts RJ

Date Published

December 2023

GIAPREZA®

Angiotensin II for the Treatment of Refractory Shock: A Matched Analysis

Author Name

Smith LM, Mentz GB, Engoren MC

Date Published

December 2023

GIAPREZA®

Angiotensin II in liver transplantation (AngLT-1): protocol of a randomised, double-blind, placebo-controlled trial

Author Name

Bokoch MP, Tran AT, Brinson EL, Marcus SG, Reddy M, Sun E, Roll GR, Pardo M, Fields S, Adelmann D, Kothari RP, Legrand M

Date Published

November 2023

GIAPREZA®

Renin as a Prognostic Marker in Intensive Care and Perioperative Settings: A Scoping Review

Author Name

Teixeira JP, Perez Ingles D, Barton JB, Dean JT, Garcia P, Kunkel SJ, Sarangarm P, Weiss NK, Schaich CL, Busse LW, Nielsen ND

Date Published

October 2023

GIAPREZA®

Renin as a Prognostic Marker in Intensive Care and Perioperative Settings: A Scoping Review

Author Name

Kotani Y, Belletti A, Maiucci G, Lodovici M, Fresilli S, Landoni G, Bellomo R, Zarbock A

Date Published

October 2023

XERAVA®

Comparative Activities of Novel Therapeutic Agents against Molecularly Characterized Clinical Carbapenem-Resistant Enterobacterales Isolates

Author Name

Teo JQ, Chang HY, Tan SH, Tang CY, Ong RT, Ko KKK, Chung SJ, Tan TT, Kwa AL

Date Published

June 2023

XACDURO®

Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK)

Author Name

Kaye KS, Shorr AF, Wunderink RG, Du B, Poirier GE, Rana K, Miller A, Lewis D, O'Donnell J, Chen L, Reinhart H, Srinivasan S, Isaacs R, Altarac D

Date Published

May 2023

GIAPREZA®

Trajectory of PaO2/FiO2 Ratio in Shock After Angiotensin II

Author Name

Wieruszewski PM, Coleman PJ, Levine AR, Davison D, Smischney NJ, Kethireddy S, Guo Y, Hecht J, Mazzeffi MA, Chow JH

Date Published

May 2023

GIAPREZA®

Initiating angiotensin II at lower vasopressor doses in vasodilatory shock: an exploratory post-hoc analysis of the ATHOS-3 clinical trial

Author Name

Wieruszewski PM, Bellomo R, Busse LW, Ham KR, Zarbock A, Khanna AK, Deane AM, Ostermann M, Wunderink RG, Boldt DW, Kroll S, Greenfeld CR, Hodges T, Chow JH

Date Published

May 2023

GIAPREZA®

A Pilot Study Of Angiotensin II As Primary Vasopressor In Critically Ill Adults With Vasodilatory Hypotension: The Aramis Study

Author Name

Emily J See, Caroline Clapham, Jasmine Liu, Monique Khasin

Date Published

May 2023

XERAVA®

Multicenter Clinical Evaluation of ETEST Eravacycline for Susceptibility Testing of Enterobacteriaceae and Enterococci

Author Name

Blanchard LS, Armstrong TP, Kresken M, Emery CL, Ying YX, Sauvonnet V, Zambardi G

Date Published

March 2023

XERAVA®

In vitro activity of eravacycline and comparator agents against bacterial pathogens isolated from patients with cancer

Author Name

Rolston K, Gerges B, Nesher L, Shelburne SA, Prince R, Raad I

Date Published

March 2023

XERAVA®

Carbapenem-Resistant Klebsiella pneumoniae: Virulence Factors, Molecular Epidemiology and Latest Updates in Treatment Options

Author Name

Karampatakis T, Tsergouli K, Behzadi P

Date Published

January 2023

XERAVA®

In Vitro Activity of Imipenem-Relebactam, Meropenem-Vaborbactam, Ceftazidime-Avibactam and Comparators on Carbapenem-Resistant Non-Carbapenemase-Producing Enterobacterales

Author Name

Bonnin RA, Bernabeu S, Emeraud C, Naas T, Girlich D, Jousset AB, Dortet L

Date Published

January 2023

GIAPREZA®

Angiotensin II for Vasodilatory Hypotension in Patients Requiring Mechanical Circulatory Support

Author Name

Wieruszewski PM, Seelhammer TG, Barreto EF, Busse LW, Chow JH, Davison DL, Gaglani B, Khanna AK, Ten Lohuis CC, Mara KC, Wittwer ED

Date Published

December 2022

GIAPREZA®

Myocardial effects of angiotensin II compared to norepinephrine in an animal model of septic shock

Author Name

Garcia B, Su F, Dewachter L, Favory R, Khaldi A, Moiroux-Sahraoui A, Annoni F, Vasques-Nóvoa F, Rocha-Oliveira E, Roncon-Albuquerque R Jr, Hubesch G, Njimi H, Vincent JL, Taccone FS, Creteur J, Herpain A

Date Published

September 2022

GIAPREZA®

A double-blind randomised feasibility trial of angiotensin-2 in cardiac surgery

Author Name

Coulson TG, Miles LF, Serpa Neto A, Pilcher D, Weinberg L, Landoni G, Zarbock A, Bellomo R

Date Published

September 2022

XACDURO®

In Vitro Activity of Sulbactam-Durlobactam against Global Isolates of Acinetobacter baumannii-calcoaceticus Complex Collected from 2016 to 2021

Author Name

Karlowsky JA, Hackel MA, McLeod SM, Miller AA

Date Published

August 2022

GIAPREZA®

Angiotensin II enhances bacterial clearance via myeloid signaling in a murine sepsis model

Author Name

Leisman DE, Privratsky JR, Lehman JR, Abraham MN, Yaipan OY, Brewer MR, Nedeljkovic-Kurepa A, Capone CC, Fernandes TD, Griffiths R, Stein WJ, Goldberg MB, Crowley SD, Bellomo R, Deutschman CS, Taylor MD

Date Published

August 2022

GIAPREZA®

Effects of angiotensin II in the management of perioperative hypotension in kidney transplant recipients

Author Name

Andrews L, Benken J, Benedetti E, Nishioka H, Pierce D, Dalton K, Han J, Shin B, Benken S

Date Published

July 2022

GIAPREZA®

The Association Between Angiotensin II and Renin Kinetics in Patients After Cardiac Surgery

Author Name

Meersch M, Weiss R, Massoth C, Küllmar M, Saadat-Gilani K, Busen M, Chawla L, Landoni G, Bellomo R, Gerss J, Zarbock A

Date Published

May 2022

GIAPREZA®

The Role of Angiotensin II in Poisoning-Induced Shock-a Review

Author Name

Chen A, Wong A

Date Published

April 2022

GIAPREZA®

Why the renin-angiotensin-aldosterone system (RAAS) in critically ill patients can no longer be ignored

Author Name

Zarbock A, Chawla L, Bellomo R

Date Published

November 2021

GIAPREZA®

Serum renin and major adverse kidney events in critically ill patients: a multicenter prospective study

Author Name

Flannery AH, Ortiz-Soriano V, Li X, Gianella FG, Toto RD, Moe OW, Devarajan P, Goldstein SL, Neyra JA

Date Published

August 2021

XACDURO®

Durlobactam, a New Diazabicyclooctane β-Lactamase Inhibitor for the Treatment of Acinetobacter Infections in Combination With Sulbactam

Author Name

Shapiro AB, Moussa SH, McLeod SM, Durand-Réville T, Miller AA

Date Published

July 2021

XACDURO®

A randomized, double-blind, placebo- and positive-controlled crossover study of the effects of durlobactam on cardiac repolarization in healthy subjects

Author Name

O'Donnell J, Maloney K, Steidler M, Morrison R, Isaacs R

Date Published

May 2021

GIAPREZA®

Evaluating the evidence for angiotensin II for the treatment of vasoplegia in critically ill cardiothoracic surgery patients

Author Name

Chow JH, Wittwer ED, Wieruszewski PM, Khanna AK

Date Published

March 2021

GIAPREZA®

A Multicenter Observational Cohort Study of Angiotensin II in Shock

Author Name

Smith SE, Newsome AS, Guo Y, Hecht J, McCurdy MT, Mazzeffi MA, Chow JH, Kethireddy S

Date Published

November 2020

XERAVA®

Efficacy and Safety of Eravacycline in Obese Patients: A Post Hoc Analysis of Pooled Data From the IGNITE1 and IGNITE4 Clinical Trials

Author Name

Asempa TE, Izmailyan S, Lawrence K, Nicolau DP

Date Published

November 2020

XERAVA®

In vitro activity of eravacycline compared with tigecycline against carbapenem-resistant Enterobacteriaceae

Author Name

Clark JA, Kulengowski B, Burgess DS

Date Published

September 2020

GIAPREZA®

Angiotensin II Infusion for Shock: A Multicenter Study of Postmarketing Use

Author Name

Wieruszewski PM, Wittwer ED, Kashani KB, Brown DR, Butler SO, Clark AM, Cooper CJ, Davison DL, Gajic O, Gunnerson KJ, Tendler R, Mara KC, Barreto EF

Date Published

August 2020

GIAPREZA®

Impaired angiotensin II type 1 receptor signaling contributes to sepsis-induced acute kidney injury

Author Name

Leisman DE, Fernandes TD, Bijol V, Abraham MN, Lehman JR, Taylor MD, Capone C, Yaipan O, Bellomo R, Deutschman CS

Date Published

August 2020

GIAPREZA®

Angiotensin II for Critically Ill Patients With Shock After Heart Transplant

Author Name

Cutler NS, Rasmussen BM, Bredeck JF, Lata AL, Khanna AK

Date Published

August 2020

XERAVA®

Antibiotic Susceptibility of NDM-Producing Enterobacterales Collected in the United States in 2017 and 2018

Author Name

Lutgring JD, Balbuena R, Reese N, Gilbert SE, Ansari U, Bhatnagar A, Boyd S, Campbell D, Cochran J, Haynie J, Ilutsik J, Longo C, Swint S, Rasheed JK, Brown AC, Karlsson M

Date Published

August 2020

GIAPREZA®

Treatment With Angiotensin II Is Associated With Rapid Blood Pressure Response and Vasopressor Sparing in Patients With Vasoplegia After Cardiac Surgery: A Post-Hoc Analysis of Angiotensin II for the Treatment of High-Output Shock (ATHOS-3) Study

Author Name

Klijian A, Khanna AK, Reddy VS, Friedman B, Ortoleva J, Evans AS, Panwar R, Kroll S, Greenfeld CR, Chatterjee S

Date Published

August 2020

GIAPREZA®

Renin and Survival in Patients Given Angiotensin II for Catecholamine-Resistant Vasodilatory Shock

Author Name

Bellomo R, Forni LG, Busse LW, McCurdy MT, Ham KR, Boldt DW, Hästbacka J, Khanna AK, Albertson TE, Tumlin J, Storey K, Handisides D, Tidmarsh GF, Chawla LS, Ostermann M

Date Published

July 2020

XACDURO®

Safety, Pharmacokinetics, and Drug-Drug Interaction Potential of Intravenous Durlobactam, a β-Lactamase Inhibitor, in Healthy Subjects

Author Name

Lickliter JD, Lawrence K, O'Donnell J, Isaacs R

Date Published

June 2020

XACDURO®

In vitro activity of sulbactam/durlobactam against global isolates of carbapenem-resistant Acinetobacter baumannii

Author Name

Seifert H, Müller C, Stefanik D, Higgins PG, Miller A, Kresken M

Date Published

June 2020

XACDURO®

In vitro activity of sulbactam/durlobactam against clinical isolates of Acinetobacter baumannii collected in China

Author Name

Yang Q, Xu Y, Jia P, Zhu Y, Zhang J, Zhang G, Deng J, Hackel M, Bradford PA, Reinhart H

Date Published

April 2020

GIAPREZA®

COVID-19 and the RAAS—a potential role for angiotensin II?

Author Name

Busse LW, Chow JH, McCurdy MT, Khanna AK

Date Published

April 2020

GIAPREZA®

Angiotensin II for the treatment of distributive shock in the intensive care unit: A US cost-effectiveness analysis

Author Name

Busse LW, Nicholson G, Nordyke RJ, Lee CH, Zeng F, Albertson TE

Date Published

March 2020

XACDURO®

Pharmacokinetics and Tolerability of Intravenous Sulbactam-Durlobactam with Imipenem-Cilastatin in Hospitalized Adults with Complicated Urinary Tract Infections, Including Acute Pyelonephritis

Author Name

Sagan O, Yakubsevitch R, Yanev K, Fomkin R, Stone E, Hines D, O'Donnell J, Miller A, Isaacs R, Srinivasan S

Date Published

February 2020

GIAPREZA®

Angiotensin I and angiotensin II concentrations and their ratio in catecholamine-resistant vasodilatory shock

Author Name

Bellomo R, Wunderink RG, Szerlip H, English SW, Busse LW, Deane AM, Khanna AK, McCurdy MT, Ostermann M, Young PJ, Handisides DR, Chawla LS, Tidmarsh GF, Albertson TE

Date Published

February 2020

XERAVA®

Eravacycline: a new treatment option for complicated intra-abdominal infections in the age of multidrug resistance

Author Name

Solomkin JS, Sway A, Lawrence K, Olesky M, Izmailyan S, Tsai L

Date Published

October 2019

XERAVA®

Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration

Author Name

Avery LM, Chen IH, Reyes S, Nicolau DP, Kuti JL

Date Published

October 2019

XERAVA®

Clinical Pharmacokinetics and Pharmacodynamics of Eravacycline

Author Name

McCarthy MW

Date Published

September 2019

Zoliflodacin

Determination of MIC Quality Control Ranges for the Novel Gyrase Inhibitor Zoliflodacin

Author Name

Miller

Date Published

August 2019

XACDURO®

Pharmacokinetics, Safety, and Tolerability of Intravenous Durlobactam and Sulbactam in Subjects with Renal Impairment and Healthy Matched Control Subjects

Author Name

O'Donnell J, Preston RA, Mamikonyan G, Stone E, Isaacs R

Date Published

August 2019

XERAVA®

Activity of cefiderocol (CFDC), ceftazidime-avibactam (CZA), and eravacycline (ERV) against carbapenem-resistant (CR) E. coli isolates from the US: Clonal Background, Resistance Genes, and Co-Resistance

Author Name

Johnston BD, Thuras P, Porter SB, Anacker M, VonBank B, Snippes Vagnone P, Witwer M, Castanheira M, Johnson JR.

Date Published

June 2019

GIAPREZA®

Sensitivity to angiotensin II dose in patients with vasodilatory shock: a prespecified analysis of the ATHOS-3 trial

Author Name

Ham KR, Boldt DW, McCurdy MT, Busse LW, Favory R, Gong MN, Khanna AK, Chock SN, Zeng F, Chawla LS, Tidmarsh GF, Ostermann M

Date Published

June 2019

XACDURO®

Targeting Multidrug-Resistant Acinetobacter spp.: Sulbactam and the Diazabicyclooctenone β-Lactamase Inhibitor ETX2514 as a Novel Therapeutic Agent

Author Name

Barnes MD, Kumar V, Bethel CR, Moussa SH, O'Donnell J, Rutter JD, Good CE, Hujer KM, Hujer AM, Marshall SH, Kreiswirth BN, Richter SS, Rather PN, Jacobs MR, Papp-Wallace KM, van den Akker F, Bonomo RA

Date Published

March 2019

XERAVA®

Eravacycline: A Review in Complicated Intra-Abdominal Infections

Author Name

Scott LJ

Date Published

February 2019

XERAVA®

IGNITE4: Results of a Phase 3, Randomized, Multicenter, Prospective Trial of Eravacycline vs Meropenem in the Treatment of Complicated Intraabdominal Infections

Author Name

Solomkin JS, Gardovskis J, Lawrence K, Montravers P, Sway A, Evans D, Tsai L

Date Published

December 2018

Zoliflodacin

Single-Dose Zoliflodacin (ETX0914) for Treatment of Urogenital Gonorrhea

Author Name

Taylor

Date Published

November 2018

XACDURO®

Plasma and Intrapulmonary Concentrations of ETX2514 and Sulbactam following Intravenous Administration of ETX2514SUL to Healthy Adult Subjects

Author Name

Rodvold KA, Gotfried MH, Isaacs RD, O'Donnell JP, Stone E

Date Published

October 2018

GIAPREZA®

Outcomes in Patients with Vasodilatory Shock and Renal Replacement Therapy Treated with Intravenous Angiotensin II

Author Name

Tumlin JA, Murugan R, Deane AM, Ostermann M, Busse LW, Ham KR, Kashani K, Szerlip HM, Prowle JR, Bihorac A, Finkel KW, Zarbock A, Forni LG, Lynch SJ, Jensen J, Kroll S, Chawla LS, Tidmarsh GF, Bellomo R

Date Published

June 2018

XACDURO®

Frequency and Mechanism of Spontaneous Resistance to Sulbactam Combined with the Novel β-Lactamase Inhibitor ETX2514 in Clinical Isolates of Acinetobacter baumannii

Author Name

McLeod SM, Shapiro AB, Moussa SH, Johnstone M, McLaughlin RE, de Jonge BLM, Miller AA

Date Published

January 2018

XACDURO®

Acinetobacter baumannii OmpA Is a Selective Antibiotic Permeant Porin

Author Name

Iyer R, Moussa SH, Durand-Réville TF, Tommasi R, Miller AA

Date Published

December 2017

XERAVA®

In Vitro Activity of Eravacycline and comparator antimicrobials against 143 recent strains of Bacteroides species

Author Name

Goldstein EJC, Citron DM, Tyrrell KL.

Date Published

October 2017

XACDURO®

Reversibility of Covalent, Broad-Spectrum Serine β-Lactamase Inhibition by the Diazabicyclooctenone ETX2514

Author Name

Shapiro AB, Gao N, Jahić H, Carter NM, Chen A, Miller AA

Date Published

August 2017

GIAPREZA®

Angiotensin II for the Treatment of Vasodilatory Shock

Author Name

Khanna A, English SW, Wang XS, Ham K, Tumlin J, Szerlip H, Busse LW, Altaweel L, Albertson TE, Mackey C, McCurdy MT, Boldt DW, Chock S, Young PJ, Krell K, Wunderink RG, Ostermann M, Murugan R, Gong MN, Panwar R, Hästbacka J, Favory R, Venkatesh B, Thompson BT, Bellomo R, Jensen J, Kroll S, Chawla LS, Tidmarsh GF, Deane AM

Date Published

August 2017

GIAPREZA®

Clinical Experience With IV Angiotensin II Administration: A Systematic Review of Safety

Author Name

Busse LW, Wang XS, Chalikonda DM, Finkel KW, Khanna AK, Szerlip HM, Yoo D, Dana SL, Chawla LS

Date Published

August 2017

XERAVA®

In Vivo Pharmacodynamic Target Assessment of Eravacycline against Escherichia coli in a Murine Thigh Infection Model

Author Name

Zhao M, Lepak AJ, Marchillo K, VanHecker J, Andes DR

Date Published

July 2017

XACDURO®

ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii

Author Name

Durand-Réville TF, Guler S, Comita-Prevoir J, Chen B, Bifulco N, Huynh H, Lahiri S, Shapiro AB, McLeod SM, Carter NM, Moussa SH, Velez-Vega C, Olivier NB, McLaughlin R, Gao N, Thresher J, Palmer T, Andrews B, Giacobbe RA, Newman JV, Ehmann DE, de Jonge B, O'Donnell J, Mueller JP, Tommasi RA, Miller AA

Date Published

June 2017

XERAVA®

A Divergent Route to Eravacycline

Author Name

Zhang WY, Che Q, Crawford S, Ronn M, Dunwoody N.

Date Published

December 2016

Zoliflodacin

Effect of Susceptibility Testing Conditions on the In Vitro Antibacterial Activity of ETX0914

Author Name

Giacobbe

Date Published

March 2016

Zoliflodacin

Update on Treatment Options for Gonococcal Infections

Author Name

Lancaster

Date Published

September 2015

Zoliflodacin

In Vitro Antibacterial Activity of AZD0914 against Human Mycoplasmas and Ureaplasmas

Author Name

Waites

Date Published

May 2015

XACDURO®

Molecular Mechanisms of Sulbactam Antibacterial Activity and Resistance Determinants in Acinetobacter baumannii

Author Name

Penwell WF, Shapiro AB, Giacobbe RA, Gu RF, Gao N, Thresher J, McLaughlin RE, Huband MD, DeJonge BL, Ehmann DE, Miller AA

Date Published

February 2015

GIAPREZA®

Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot study

Author Name

Chawla LS, Busse L, Brasha-Mitchell E, Davison D, Honiq J, Alotaibi Z, Seneff MG

Date Published

October 2014

XERAVA®

Phase 2, Randomized, Double-Blind Study of the Efficacy and Safety of Two Dose Regimens of Eravacycline versus Ertapenem for Adult Community-Acquired Complicated Intra-Abdominal Infections

Author Name

Solomkin JS, Gardovskis J, Lawrence K, Montravers P, Sway A, Evans D, Tsai L

Date Published

April 2014

XERAVA®

Process R&D of Eravacycline: The First Fully Synthetic Fluorocycline in Clinical Development

Author Name

Ronn M, Zhu Z, Hogan P, Zhang W, Niu J, Katz CE, Dunwoody N, Gilicky O, Deng Y, Hunt DK, He M, Chen C, Sun C, Clark RB, Xiao X

Date Published

April 2013

XERAVA®

Target- and Resistance-Based Mechanistic Studies with TP-434, a Novel Fluorocycline Antibiotic

Author Name

Grossman TH, Starosta AL, Fyfe C, O'Brien W, Rothstein DM, Mikolajka A, Wilson DN, Sutcliffe JA.

Date Published

February 2012

XERAVA®

Fluorocyclines. 1. 7-Fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: A Potent, Broad Spectrum Antibacterial Agent

Author Name

Xiao XY, Hunt DK, Zhou J, Clark RB, Dunwoody N, Fyfe C, Grossman TH, O'Brien WJ, Plamondon L, Rönn M, Sun C, Zhang WY, Sutcliffe JA

Date Published

December 2011

Request Medical Information

To speak to a Innoviva Specialty Therapeutics Information Professional, please visit our Contact page.

Report a Product Complaint

To report a complaint about an Innoviva Specialty Therapeutic product, please visit our Product Complaint page.

Report an Adverse Event

To report an adverse event with an Innoviva Specialty Therapeutic product, please visit our Adverse Event page.